## Introduction

- Announcer: Welcome to Mayo Clinic's ECG segment Making Waves Continuing Medical Education podcast.

Join us for a lively discussion on the latest

and greatest in the field of Electrocardiography.

We'll discuss some of the exciting

and innovative work happening at Mayo Clinic

and beyond with the most brilliant minds in the space,

and provide valuable insights

that can be directly applied to your practice.

## Welcome

- Dr. Anthony Kashou: Welcome to Mayo Clinic's ECG segment making waves.

In this episode, we explore the rapidly evolving field

of atrial fibrillation therapy,

focusing on pulse field ablation,

or PFA, a modality that has transformed the landscape

of atrial fibrillation catheter ablation.

Joining us as an expert

and cardiac electrophysiologist here

to provide insights into

how pulse field ablation differs from traditional thermal

based techniques, its recurrence rates,

and the most common causes of reduced procedures.

We'll also discuss how pulse field ablation may evolve in

the coming years to improve durability and outcomes.

But first, let me introduce you to our guest today. Dr.

Nicholas Tan completed his undergraduate degree in

biomedical engineering at Johns Hopkins University,

following which he completed medical school

and a master's degree in biomedical investigation from the

Cleveland Clinic Lerner College of Medicine.

He then did his internal medicine, cardiovascular medicine

and cardiac electrophysiology training here at the Mayo

Clinic in Rochester in July of 2023.

He was hired on staff within the Division

of Heart Rhythm Services.

His research interests include developing device-based

therapies for pacing defibrillation

and cardiac ablations, as well

as electrophysiology considerations in cancer patients.

Additionally, he is completing a master's degree in medical

device innovation from the University of Minnesota.

Dr. Tan, thank you so much for joining us today.

- Dr. Nicholas Tan: Thanks a lot for having me.

- Dr. Anthony Kashou: You know, well, you know, PFA or Pulse field ablation is really changing the landscape. But before we get into it, just to get our audience on the same page, let's kind of go to the basics.

What exactly is pulse field ablation

and how is it different from the more established methods like radiofrequency or cryoablation?

- Dr. Nicholas Tan: That's a great question.

So just to go back even further a little bit, cardiac of patient first started with DC shocks.

So direct current energy that was applied to the tip

of a catheter to induce myocardial ablation.

Now obviously that was a little traumatic

when it first occurred in 1980 or so.

And so radio frequency ablation

developed from there where you basically

deliver heat energy to the tip of a catheter

to ablate ablate tissue.

Cryoablation is sort of on the opposite, on end of the spectrum where you're cooling tissue to the point where you cause myocardial death.

Now, both these modalities have

something in common in that heat transfer always occurs

and heat will always move in other directions

and usually in directions that you don't don't want.

So you can cause collateral damage to the coronary arteries,

to nerves to the esophagus,

and those are complications that we really try

to shy away from.

Now, pulse fuel ablation is different in that instead of delivering a long pulse of electricity,

you're delivering multiple short pulses

to your target tissue.

And it turns out that cardiomyocytes tend

to be much more sensitive

to its effects biologically compared

to most other tissue types.

And so what that hap, what happens then is

that you can induce myocardial death either through necrosis

or through apoptosis without causing any heat transfer.

And, and this has led to the development

of these PFA based catheters

where you can effectively kill myocardial tissue without

injuring any of the neighboring structures. So because of that, it has significantly transformed the way that we have practiced PFA was clinically used in Europe or has been used in Europe for the past few years, and we recently had it f FDA approved.

And it's really transformed our practice in many ways.

- Dr. Anthony Kashou: And, and it, it seems like this is, you know, already as you mentioned, transforming practices in terms of your practice and you know,

what you've seen across colleagues.

How do you see how this has changed in terms of recurrence rates for somewhat the atrial fibrillation if they come and, you know, are having a PBI with this method versus prior techniques?

Yeah. Are we seeing better outcomes?

Are the challenges similar to what you descri

Are the challenges similar to what you described previously with, you know, the heat exchange Recurrence Rates

- Dr. Nicholas Tan: In terms of recurrence rates? That's something in the US at least, that's something that we are starting to learn about because for the most part, most centers started using PFA only last year after it was FDA approved.

And so this year is when we start seeing the one year recurrences, but based on prior trial data and based on data from Europe, what we have ascertained is that the recurrence rates pulling PFA is fairly comparable to the other previous modalities.

And this is, and,

and keep in mind that this is a relatively new technology. This is including operators who may not be necessarily as experienced with PFA compared to other, the other established modalities.

And despite that, recurrence rates tend to be similar.

And so generally speaking, the numbers that have
of shaken up across these studies
and trials is about 30% over a one year course.

And, and again, that is very, very comparable to what we see with RF or cryoablation.

- Dr. Anthony Kashou: And so 30% recurrence after a year, similar to other modalities and ablation techniques, yet probably minimizing the risk of more serious injuries, maybe the esophageal, you know,

complications or, or things along that, that is correct.

In terms, in terms of, you know, redo

after this index pulse field ablation,

are you seeing also similar reasons

for why there might be recurrence?

- Dr. Nicholas Tan: For the most part, that,

that certainly seems to be the case.

Reasons for recurrence

Again, we, we need more data from the US side

to, to see if there are any significant differences between

that and this other studies that performed elsewhere.

But for the most part, the recurrences, about two thirds

of them would tend to occur in the pulmonary veins.

So again, the, the, the main goal of

AFib catheter ablation is to target the pulmonary veins,

hence the main pulmonary vein isolation of PBI.

So it turns out that in the patients that you do bring back

to the lab or redo procedure

after an initial PFA ablation,

the pulmonary veins are the most common sources of,

of these, these brain two, these recurrences.

And, and so that may be due to incomplete ablation

with the initial ablation procedure

or some healing that occurs subsequently, it may have to do

with the, the differences in terms of

how we ascertain whether

we cause reversible versus irreversible

damage to the muscle.

And that is a new one that we are starting

to understand a little bit more.

And then in the other one third of cases,

you have other areas that can be, that can serve

as triggers for AFib.

And, and again, those will require t novo ablation such

as the posterior wall.

Sometimes you can have floods that occur as well, and,

and those will need to be assessed

and dealt with accordingly.

Dr. Anthony Kashou: And so now that we're learning more, as you mentioned,

about a year into this, starting to collect some of this

recurrence data

and understanding more maybe similar recurrence rates,

where do you see the,

the field going over the next few years?

Do you see kind of new tools and protocols as you better understand the underlying, you know, process of, of what's going on New tools and protocols or what are your thoughts?

- Dr. Nicholas Tan: It's this, this podcast is actually timely and we very recently acquired a novel catheter system from Medtronic, so it's called the Ferra system.

It's, it's a mapping

and ablation catheter that can perform both RF ablation and PFA.

So how this can be helpful is that there are certain areas that are probably still better for

RF ablation such as flood lines.

One main issue that we see with PFA in, in areas where the coronary arteries are close by is that you can actually cause the coronary arteries to spasm and you don't normally get that effect with RFA. So having a catheter that can toggle between PFA and RFA is very helpful in this regard.

And that's for atrial ablations.

So we are also starting to look into ventricular ablations for PFA using PFA,

and again, two new tools are being developed to try and tackle that problem.

And again, that's a totally different beast because when you think about the atrial tissue, it's, it's relatively thin.

Ventricular tissue can be much thicker, it's more complex. So that will be another growing arena of research and that that, you know, is kind of right for the taking at this point.

- Dr. Anthony Kashou: Wonderful. Wow.

Well, it's an exciting field, a lot of development.

And you know, Dr.

Tan, thank you so much for joining us and sharing about the innovation in PFA Pulse field ablation in its impact on atrial fibrillation therapy.

Dr. Tan provided valuable insights on how pulse field ablation differs from traditional ablation techniques, the challenges of recurrence rates. And we're still learning a lot about that,

about a year into this that's similar

that's still another area that we're trying to understand. He also shared the vision, you know, of the future of pulse field ablation, these new tools that are helping us map and understand it.

And the ventricular arrhythmias are another beast, as he mentioned.

Dr. Tan, thank you so much for sharing your expertise and providing a clear and thoughtful overview of this transformative technology. We look forward to having you back in the future to discuss further developments in the field. Thank you again.

- Dr. Nicholas Tan: Thanks a lot. Appreciate it.

and the most common causes of redo,

- Announcer: Thank you for joining us today.

We invite you to share your thoughts
and suggestions about the
podcast at cveducation.mayo.edu.

Be sure to subscribe to a Mayo Clinic cardiovascular CME
podcast on your favorite platform,
and tune in every other week
to explore today's most pressing electrocardiography topics
with your colleagues at Mayo Clinic.

This has been a Mayo Clinic podcast.